Photo from wikipedia
The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic… Click to show full abstract
The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease. We report herein the pre‐specified subgroup analysis in patients with heart failure (HF).
Keywords:
patients resistant;
use;
chronic kidney;
heart failure;
resistant hypertension
Journal Title: European Journal of Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!